Forty Seven (NASDAQ:FTSV) had its price objective increased by equities research analysts at Morgan Stanley from $25.00 to $26.00 in a research note issued on Thursday, Stock Target Advisor reports. The brokerage presently has an “overweight” rating on the stock. Morgan Stanley’s price objective would indicate a potential upside of 74.85% from the company’s current price.

A number of other analysts have also recently weighed in on the stock. Zacks Investment Research raised shares of Forty Seven from a “sell” rating to a “hold” rating in a research report on Thursday, October 4th. Oppenheimer started coverage on shares of Forty Seven in a research report on Monday, July 23rd. They issued an “outperform” rating and a $35.00 price objective for the company. Credit Suisse Group started coverage on shares of Forty Seven in a research report on Monday, July 23rd. They issued an “outperform” rating and a $24.00 price objective for the company. Finally, Canaccord Genuity started coverage on shares of Forty Seven in a research report on Monday, July 23rd. They issued a “buy” rating and a $22.00 price objective for the company. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Forty Seven currently has an average rating of “Buy” and an average price target of $26.75.

Shares of Forty Seven stock opened at $14.87 on Thursday. Forty Seven has a twelve month low of $12.16 and a twelve month high of $16.86.

Forty Seven (NASDAQ:FTSV) last announced its quarterly earnings results on Monday, August 13th. The company reported ($2.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($1.84). Equities research analysts expect that Forty Seven will post -2.96 earnings per share for the current fiscal year.

In other news, major shareholder Peter Nieh acquired 67,500 shares of the firm’s stock in a transaction on Friday, August 17th. The stock was bought at an average cost of $15.18 per share, with a total value of $1,024,650.00. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Ravi Mhatre acquired 166,858 shares of the firm’s stock in a transaction on Thursday, August 23rd. The stock was purchased at an average cost of $15.08 per share, with a total value of $2,516,218.64. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 300,900 shares of company stock valued at $4,540,995.

Hedge funds have recently modified their holdings of the company. Point72 Hong Kong Ltd bought a new position in shares of Forty Seven during the second quarter worth about $120,000. Waddell & Reed Financial Inc. bought a new position in shares of Forty Seven during the second quarter worth about $160,000. Janus Henderson Group PLC bought a new position in shares of Forty Seven during the second quarter worth about $160,000. DAFNA Capital Management LLC bought a new position in shares of Forty Seven during the second quarter worth about $160,000. Finally, TD Asset Management Inc. bought a new position in shares of Forty Seven during the second quarter worth about $215,000. 41.05% of the stock is currently owned by institutional investors and hedge funds.

About Forty Seven

Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; and FSI-189, an antibody that binds to SIRPa for the treatment of solid tumors.

Featured Article: Why is the ex-dividend date different from the record date?

Stock Target Advisor

Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.